GRF (1-29) amide (rat) CAS NO.91826-20-9
GRF (1-29) amide (rat) CAS NO.91826-20-9
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | GRF (1-29) amide (rat) |
| CAS NO. | 91826-20-9 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C₁₅₅H₂₅₁N₄₉O₄₀S |
| Molecular Weight | 3473.1 g/mol |
| Purity (RP-HPLC) | ≥ 98.0% |
| Solubility | Freely soluble in deionized water (pH 4.0–7.0) or 0.1 M acetic acid; partially soluble in DMSO (≤2 mg/mL) to avoid precipitation. |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | Rat-specific GRF (1-29) amide, a 29-amino-acid peptide and potent agonist of the growth hormone secretagogue receptor 1a (GHS-R1a; rat, EC₅₀: 0.1–1 nM). C-terminal amidation enhances stability and receptor binding. Stimulates growth hormone (GH) release from the anterior pituitary via GHS-R1a-mediated Ca²⁺ influx and cAMP elevation. Species-optimized for rat models, critical for comparative endocrinology and translational research. |
| Storage Conditions | Store at -20°C in a tightly sealed, light-protected container; avoid moisture and repeated freeze-thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
GHS-R1a Activation: Binds to the growth hormone secretagogue receptor 1a (GHS-R1a) in rats with high affinity (EC₅₀: 0.1–1 nM), triggering Gq/11 protein-coupled signaling cascades.
GH Secretion: Stimulates growth hormone (GH) release from the anterior pituitary gland via GHS-R1a-mediated Ca²⁺ influx and cAMP elevation, bypassing hypothalamic somatostatin inhibition.
C-Terminal Amidation: The C-terminal amidation (NH₂) enhances peptide stability in biological fluids and strengthens receptor binding, making it more potent than non-amidated forms.
2.PRODUCT INDICATIONS
Rat Endocrinology Research: Studying GH regulation, puberty, aging-related hormonal changes, and GH deficiency disorders in rat models.
Comparative Studies: Investigating species differences in GRF-GHS-R1a interactions between rats, humans, and other animals.
Preclinical Drug Development: Screening GHS-R1a agonists/antagonists for treating growth disorders (e.g., dwarfism) or metabolic diseases (e.g., cachexia) in rat models.
3.CLINICAL EFFICACY OF PRODUCT
GH Secretion: In rat pituitary cell cultures, GRF (1-29) amide increased GH release by 5–10x (1 nM concentration) vs. baseline.
Linear Growth: In GH-deficient rat models, it promoted 30–50% greater body length increase over 8 weeks vs. untreated controls.
Muscle Function: In aged rat models, it improved grip strength by 20–30% and lean muscle mass by 15–25% within 4 weeks.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
May 25, 26
Premium API Oxandrolone Ucinky Manufacturing
Premium API Oxandrolone Ucinky Manufacturing Leading global supplier of high-purity chemical raw materials for pharmaceutical grade Oxandrolone Ucinky, combining precision engineering with industrial scale. 5000 kg Annual Output 120 Countries Served 5 Days Sample Lead Time 99.7 On-Time Delivery Industrial Precision Pure Chemical Synthesis Engineering the future of pharmaceutical intermediates with unmatched stability. Our facility stands as a global leader in the oxandrolone ucinky sector, utilizing CRYOGENIC CRYSTALLIZATION and advanced chromatography to ensure an assay purity exceeding 99.8. We integrate a fully automated closed-loop system that eliminates human error and contamination.
May 22, 26
Clinical Benefits and Applications of Oxandrolone Therapy
Oxandrolone therapy represents a sophisticated intersection of endocrine science and regenerative medicine, primarily utilized to address muscle wasting and metabolic dysfunction. In the global pharmaceutical landscape, this specific approach to androgen therapy is valued for its unique ability to promote protein synthesis while exhibiting a lower androgenic profile compared to traditional steroids, making it a critical tool for patients recovering from severe trauma or chronic illness. From a clinical perspective, understanding the nuances of oxandrolone therapy is essential for optimizing patient outcomes in weight gain and tissue repair.
May 20, 26
Clinical Benefits and Production of Oxandrolone Steroid
The global pharmaceutical landscape has seen a significant rise in the demand for highly specialized anabolic agents, among which the oxandrolone steroid stands out due to its unique chemical profile and therapeutic versatility. As a modified version of dihydrotestosterone, this compound provides a potent means of addressing muscle wasting and metabolic deficits, making it a critical asset in both clinical rehabilitation and advanced physiological research. Understanding the nuances of this synthetic compound is essential for healthcare providers and researchers alike, as it balances efficacy with a relatively lower androgenic profile compared to other steroids.
